Ned Pagliarulo
Lead Editor | @NedPagliaruloNed is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University.
2299 articles by Ned Pagliarulo
-
Armed with new gene therapy tools, a biotech startup promises a better way to target muscle diseases
June 8, 2023 -
Closing ASCO: AstraZeneca’s ‘very special’ meeting, more CAR-T survival data and Pfizer’s PARP play
June 6, 2023 -
AstraZeneca study points to new uses for targeted cancer drug Enhertu
June 5, 2023 -
J&J sees trial data supporting earlier CAR-T use in multiple myeloma
June 5, 2023 -
Bristol Myers data make case for earlier use of bone marrow disease drug
May 25, 2023 -
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
May 25, 2023 -
Novartis buys rare disease gene therapy from Avrobio
May 22, 2023 -
Gilead picks former Roche executive to run cell therapy unit Kite
May 17, 2023 -
Siren emerges from stealth with plans to marry gene therapy to cancer immunotherapy
May 17, 2023 -
Biotech startup Ray raises $100M for vision-restoring gene therapies
May 16, 2023 -
FDA panel narrowly backs approval of Sarepta’s Duchenne gene therapy
May 12, 2023 -
Gilead acquires San Diego startup for early-stage cancer, immune drugs
May 9, 2023 -
EQRx resets strategy, abandoning plans to disrupt drug pricing
May 8, 2023 -
Catalent cuts outlook, delays results as it reveals new hurdles
May 8, 2023 -
Apellis reports strong start for new vision loss drug
May 5, 2023 -
Lilly drug slows Alzheimer’s decline in large study
May 3, 2023 -
Travere set back by study failure of kidney disease drug
May 2, 2023 -
Initial launches with $75M and a new idea for targeting problematic proteins
May 1, 2023 -
AbbVie weathers first months of biosimilar challenge to top-selling Humira
April 28, 2023 -
Sangamo to lay off 120 as it pares pipeline
April 27, 2023 -
Morphic shares swing on study data for drug viewed as ‘oral Entyvio’
April 25, 2023 -
J&J’s consumer health spinoff seeking $3B stock offering in test of IPO market
April 25, 2023 -
Ionis, AstraZeneca detail data backing rare disease rival to Alnylam drugs
April 24, 2023 -
Startup Abdera raises $110M to fuel radiopharmaceutical research
April 20, 2023 -
J&J study data show dramatic benefit to multiple myeloma cell therapy
April 19, 2023